Cerca una sperimentazione clinica
Altra/e opzione/i di ricerca
12 Risultato/i
Sperimentazione in fase di reclutamento
= 
; Sperimentazione in corso
= 
; Finanziato da un ente associato a IRDiRC = 
Sperimentazioni cliniche nazionali
BELGIO
VLAAMS BRABANT
LEUVEN
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - BE
University Hospitals Leuven - Gasthuisberg
UZ Leuven
FRANCIA
ILE-DE-FRANCE
PARIS
MSC-LES: Treatment of severe refractory systemic lupus erythematosus by injection of allogeneic mesenchymal stem cells derived from the umbilical cord
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
Unité de Médecine interne, Maladies Auto-immunes et Pathologie Vasculaire
GERMANIA
Hessen
FRANKFURT AM MAIN
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - BE
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
GERMANIA
Niedersachsen
HANNOVER
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - BE
Medizinische Hochschule Hannover
Klinik für Nieren- und Hochdruckerkrankungen
GERMANIA
Nordrhein-Westfalen
ESSEN
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - BE
Universitätsklinikum Essen
GERMANIA
Rheinland-Pfalz
MAINZ
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis - BE
Universitätsmedizin Mainz
GIAPPONE
JAPAN
ADDRESS : NOT PROVIDED - JP
A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Systemic Lupus Erythematosus - JP
Institution: Information not provided - JP
GIAPPONE
JAPAN
HYOGO
BRAVE II: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus - JP
Eli Lilly Japan K.K.
REGNO UNITO; GRAN BRETAGNA
Cambridgeshire
CAMBRIDGE
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis-GB
Addenbrooke's Hospital
Addenbrookes Hospital
Sperimentazioni cliniche internazionali
BELGIO
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis
Bristol Myers Squibb International Corporation
BELGIO
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Systemic Lupus Erythematosus
Bristol Myers Squibb International Corporation
STATI UNITI
Indiana
INDIANAPOLIS